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Background: We usually report five-year survival from population-based cancer registries in Japan; however these
survival estimates may be pessimistic for cancer survivors, because many patients with unfavourable prognosis die
shortly after diagnosis. Conditional survival can provide relevant information for cancer survivors, their family and
oncologists.
Methods: We used the period approach to estimate the latest 10-year survival of 38,439 patients with stomach,
colorectal, lung, breast and prostate cancer diagnosed between 1990 and 2004 and followed-up from 2000–04 in
Osaka, Japan. Conditional survival is an estimate, with the pre-condition of having already survived a certain length
of time. Conditional five-year relative survival of one to five years after diagnosis was calculated by site, age and
stage for survivors under the age of 70.
Results: Five-year relative survival for stomach cancer was 60%. Conditional five-year relative survival was 77% one
year after diagnosis and 97% five years after diagnosis. This means that 97% of patients who survive five years after
diagnosis can survive a further five years. Conditional five-year relative survival improved successively with each
additional year that patients lived after diagnosis for stomach, colorectal and lung cancer. These figures for breast
and prostate cancer were stable at high survival. Liver cancer did not show an increase in conditional five-year
survival.
Conclusion: Conditional five-year survival is a relevant figure for long-term cancer survivors in Japan. It is important
for population-based cancer registries to provide figures which cancer patients and oncologists really need.
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In recent years cancer patients have been able to survive
for longer than those diagnosed a few decades ago. We
usually report five-year relative survival rates after diag-
nosis in the annual reports of regional cancer registries
in Japan. However, these survival estimates may be pes-
simistic for cancer survivors, because many patients with
unfavourable prognosis die shortly after diagnosis.
Conditional survival analysis is a method to estimate
survival rates, with the pre-condition of having already
survived a certain length of time. The figures have been* Correspondence: itou-yu2@mc.pref.osaka.jp
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reproduction in any medium, provided the orreported in the US and other countries, and can provide
cancer survivors, their families and oncologists with
more relevant information [1-11].
In 2007, the Basic Plan to Promote Cancer Control
Programs of Japan was approved, following the establish-
ment of the Cancer Control ACT of Japan in 2006. Im-
provement of cancer care support and information
services is one of the specific goals of this program [12].
Longstanding population-based cancer registry data can
provide this type of useful information to cancer survi-
vors. We used cancer patient data from the Osaka Can-
cer Registry, which has a long history and covers the
largest population in Japan, to report conditional sur-
vival in patients with six major cancers by age group and
stage at diagnosis.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Data sources
We analysed 38,439 cases diagnosed with first, primary,
invasive malignant tumour of the following cancers:
stomach (International Classification of Diseases, 10th
revision code [13]: C16), colorectal (C18-C20), lung
(C33, C34), breast (C50, female only) and prostate (C61)
from 1990–2004. They were followed up between 2000
and 2004 in Osaka, Japan, from the Osaka Cancer Regis-
try database. We limited the data to patients who were
diagnosed at age 15 to 69 years. Patients over 70 years of
age at diagnosis were excluded from the analyses as
long-term survival estimates are unstable for older age
groups. In the Osaka Cancer Registry, we followed pa-
tients up using the death certificate database for residents
in Osaka prefecture. However, if patients had moved out-
side the Osaka Prefecture after diagnosis the death certifi-
cate database would be unable to capture their details. In
these cases resident registries were used to follow the pa-
tients up. Residents in Osaka-city (30% of total population
of Osaka prefecture) were not followed-up using residence
registries before 1993, so patients who lived in Osaka-city
were excluded from the analysis. Cases diagnosed from
1990 to 1999 were followed up for 10 years after diagnosis,
whereas follow-up was limited to 5 years for those diag-
nosed from 2000 to 2004 (Figure 1).
Statistical analysis
First, we estimated ten-year relative survival using the
Osaka Cancer Registry data by sex, age group (15–49,
50–59 and 60–69 years old) and stage at diagnosis
(localised, regional and distant metastasis). Relative sur-
vival is a ratio of the observed survival (overall survival)
and the survival that would have been expected if the
cancer patient had only experienced the normal (back-
ground) mortality of the general population in which
they live [14]. In this study we estimated relative survival
using the maximum likelihood method developed by
Esteve et al. [15] and the publicly available StataFigure 1 Illustration of period approach to estimate up-to-date long-programme strel [16]. We derived the expected survival
from complete (single-year-of-age) national population
life tables by sex [17]. We used conventional 10-year
relative survival estimating based on data from patients
who were diagnosed from1995-1999 and were followed-
up over 10 years (dashed line in Figure 1). However, cal-
culation of long-term survival using the conventional
method is outdated. We therefore used period analysis
to derive more up-to-date long-term survival using data
from recently followed-up cancer patients [18]. In this
study, we used data from cancer patients who were diag-
nosed from 1990–2004 and followed-up between 2000
and 2004 (solid black line, in Figure 1).
Second, we calculated conditional five-year survival for
patients who survived for 0 to 5 years after diagnosis using
ten-year cumulative relative survival. To estimate the five-
year conditional survival of patients who survived x years,
the (x + 5)-year cumulative survival rates is divided by the
x-year cumulative survival. In the other words, conditional
five-year survival is five-year survival of the patients who
are alive several years after diagnosis [2,10].
Third, for missing stage cases, we used the multiple im-
putation approach [19]. We examined the characteristics
of patients with missing stage before multiple imputation,
then we assumed the mechanism of missingness as Miss-
ing At Random. The relative survival of the ten completed
data sets contained the imputed value of stage for cases
with missing information (6.4-17.1%). The imputation
model was a multinomial logistic regression including
follow-up time, vital status, period of diagnosis, age at
diagnosis, and interactions between follow-up time and
other factors. Rubin’s rules were applied to estimate rela-
tive survival and standard errors combining the ten com-
pleted data sets. All statistical analyses were performed
using the standard statistical package Stata Ver. 12.1 [20].
Results
The characteristics of patients we analysed are shown in
Table 1. Conditional five-year survival for all stageterm survival.
Table 1 Characteristic of cancer patients for selected sites of cancer in Osaka, Japan in 1990–2004
Stomach Colon/rectum Liver Lung Breast Prostate
N % N % N % N % N % N %
Total 10278 100.0 8411 100.0 4800 100.0 6397 100.0 7229 100.0 1324 100.0
Age
15-49 1266 12.3 897 10.7 296 6.2 549 8.6 2591 35.8 6 0.5
50-59 3442 33.5 2830 33.6 1344 28.0 2024 31.6 2752 38.1 214 16.2
60-69 5570 54.2 4684 55.7 3160 65.8 3824 59.8 1886 26.1 1104 83.4
Stage (before imputation)
Localised 4863 50.7 3568 45.3 2897 72.8 1426 23.8 3747 57.3 785 65.4
Regional 2758 28.8 2577 32.7 663 16.7 2167 36.2 2439 37.3 175 14.6
Distant 1972 20.6 1728 21.9 421 10.6 2397 40.0 350 5.4 241 20.1
Missing 685 (6.7) 538 (6.4) 819 (17.1) 407 (6.4) 693 (9.6) 123 (9.3)
Stage (after imputation)
Localised 5202 50.6 3817 45.4 3436 71.6 1511 23.6 4139 57.3 865 65.3
Regional 2960 28.8 2757 32.8 818 17.0 2304 36.0 2701 37.4 196 14.8
Distant 2116 20.6 1837 21.8 546 11.4 2582 40.4 389 5.4 263 19.9
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in Figure 2. For stomach cancer, the five-year relative
survival for all cases is 60% at diagnosis. 77% of patients
who survived one year (one-year survivor) can survive
an additional five years. Conditional five-year survival at
two years after diagnosis was 87%. Conditional five-year
survival at five years after diagnosis was 97%. This
means 97% of the stomach cancer patients who survived
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Figure 2 Conditional five-year survival for all patients diagnosed in 1Colorectal and lung cancer showed similar results to
stomach cancer patients. However, conditional five-year
survival for liver cancer did not increase after any period
post diagnosis. Conditional survival for breast and pros-
tate cancer patients was stable at around 85-90%.
By age group
Results by age group are shown in Figure 3. Most cancer
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Figure 3 Conditional five-year survival of the patients diagnosed in 1990–2004 and followed-up in 2000–2004 in Osaka, Japan: by age group.
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creased in the young group (under the age of 50). In
prostate cancer patients, the older age group (60–69
years old) showed better conditional survival than the
younger age group (50–59 years old).
By stage
Figures for conditional survival by stage at diagnosis
were different for different cancers (Figure 4). In all ex-
cept liver cancer patients, the figures for conditional sur-
vival for localised patients were high at around 90%. In
stomach, colorectal and lung cancer patients, even the re-
gional and distant metastasis cases showed high five-year
survival for five-year survivors. In liver cancer patients,
even localised cases showed low conditional five-year sur-
vival. In breast and prostate cancer patients, conditional
five-year survival for each stage was stable.
Discussion
Conditional five-year relative survival improved succes-
sively with each additional year that patients lived fol-
lowing diagnosis for stomach, colorectal and lung
cancer. This pattern was also similar to the regional ordistant metastasis cases. Breast and prostate cancer
showed different trends; conditional five-year survival
was stable at a higher level. Liver cancer did not show
any increase in conditional five-year survival.
Stomach and colorectal cancer
For stomach and colorectal cancer patients who survived
more than five years after diagnosis, conditional five-
year survival was close to 100%. This means that those
who survived five years would have the same survival
probability as the general population, i.e. they can be
considered as ‘cured’ of cancer. Although it is difficult to
define clinical ‘cure’ at the individual level, we can define
the concept of ‘cure’ at population level [21,22]. Condi-
tional five-year survival for localised cases was stable at
more than 90%. Those for regional or distant metastasis
increased according to the number of years since diag-
nosis. Even late stage patients who survive a few years
have a chance of living another five years.
Lung cancer
Conditional survival in lung cancer patients increased
according to the additional years after diagnosis.
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Figure 4 Conditional five-year survival of the patients diagnosed in 1990–2004 and followed-up in 2000–2004 in Osaka, Japan: by
stage at diagnosis.
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and colorectal cancer. This was because lung cancer pa-
tients have a higher risk of death due to complications
related to cancer or cancer risk (smoking), such as ische-
mic heart disease.Breast and prostate cancer
Conditional five-year survival rates for all cases of both
breast and prostate cancer were around 80-90%, due to
the higher proportion of localised patients in all cases.
Conditional five-year survival for localised prostate can-
cer patients slightly decreased five years after diagnosis.
This could be partly explained by the recurrence or pro-
gression of tumours during long-term follow-up. For
these cancers, we need to follow-up patients for a longer
period.Liver cancer
Conditional survival for liver cancer was much lower
than for other cancers at any stage or age after severalyears. Even in localised patients, conditional five-year
survival was less than 40% after five years. This is prob-
ably because many liver cancer patients experienced a
recurrence of cancer, or died from liver cirrhosis or liver
failure related to the hepatitis B or C virus.Effect of age and stage at diagnosis
Trends in conditional survival by age group were quite
similar except for liver and prostate cancer. For most
cancers, age did not significantly affect conditional sur-
vival. In the case of liver cancer, conditional survival for
young patients (15–49 years old) was higher than for old
patients (60–69 years old) after several years. This could
be explained by the fact that the old patients had been
exposed to hepatitis viruses for long time; as a result,
they tended to develop liver cirrhosis and liver failure
more than young patients. Conditional survival of young
prostate cancer patients (50–59 years old) was lower
than old patients (60–69 years old). This is probably be-
cause young patients are diagnosed at a more advanced
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tasis was 35.2% in 50-59-year-old patients and 28.3% in
60-69-year-old patients).
The conditional survival curve was different by stage;
stage at diagnosis was an important prognostic factor.
Conditional survival for localised patients was stable at
85-95%, while for regional and distant metastasis pa-
tients it increased after several years of diagnosis.
Trends in conditional survival for breast and colorectal
cancer patients in Osaka were similar to other countries
(shown in Additional file 1: Figures S1-S4 from Australia
[2,6], US [8], Canada [5,11] and European countries
[3,9]). Conditional survival for prostate cancer at all
stages in Osaka was lower than other countries. This is
due to the low proportion of localised patients in Japan
compared to other countries. Conditional survival of
stomach cancer for all stage and localised in Osaka was
higher than in Australia [2]. Stomach cancer patients in
Osaka were diagnosed at an earlier stage than in
Australia (e.g. 51% patients diagnosed at localised stage
in Osaka, 28% in Australia). In addition, approximately
half of the stomach cancer patients in Japan were diag-
nosed at T1 (UICC TNM classification) [23]. Therefore
we can estimate a higher proportion of T1 in localised
patients in Osaka than in Australia. Higher conditional
survival for localised patients can be partly explained by
differences in tumour. This may be due to stomach can-
cer screening programmes [24] and wide use of endos-
copy in clinical settings in Japan. Conditional survival of
localised lung cancer in Osaka was higher than in other
countries. This could be explained by differences in
tumour size and histology [25,26]. Conditional survival
for liver cancer patients in Canada increased some years
after diagnosis [11], while in Osaka it was stable at low
survival. This can be explained by the differences in etio-
logical factor among these countries. In the US and
Canada, prevalence of hepatitis B or C viruses in liver
cancer cases was lower than in Japan [27]. Liver cancer
patients in Japan might have greater likelihood of liver
failure or hepatitis-related cirrhosis than those in the US
and Canada.
Conditional five-year survival for stomach and colo-
rectal cancer patients who were alive five years after
diagnosis was about 100%; this means those patients
have similar survival probability to the general popula-
tion. Therefore those patients can be considered as
‘cured’. For other sites of cancer, further long-term
follow-up time may be needed to estimate ‘cured’ time.
Conditional survival is an important statistic for plan-
ning long-term life after diagnosis, not only for cancer
patients and their families, but also patients with other
diseases. However, a population-based disease registry
system, such as the population-based cancer registry, is
essential to estimate this type of statistic.Conclusion
Conditional five-year survival is a relevant figure for
long-term cancer survivors in Japan. It is important for
population-based cancer registries to provide figures
which cancer patients and oncologists really need.
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Additional file 1: Figure S1-S4. Comparison of conditional survival
between countries, by site and stage.
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